Effects of geldanamycin on HIF-1α mediated angiogenesis and invasion in prostate cancer cells

Prostate Cancer and Prostatic Diseases

Volumn 9, Issue 2, 2006, Pages 126-135

  Alqawi, O ^a   Moghaddas, M ^a   Singh, Gurmit ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Angiogenesis; Cell invasion; HIF 1 ; Hypoxia; MMPs; VEGF

Indexed keywords

ANSAMYCIN DERIVATIVE; BENZOQUINONE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR 1; LUCIFERASE; MESSENGER RNA; OXYGEN; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER CELL; CELL DIVISION; CELL HYPOXIA; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; CULTURE MEDIUM; DATA ANALYSIS; DRUG MECHANISM; ENDOTHELIUM CELL; GENE CONSTRUCT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOXIA; INCUBATION TEMPERATURE; INCUBATION TIME; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN INDUCTION; REPORTER GENE; TRANSCRIPTION REGULATION; TUMOR CELL; TUMOR GROWTH; UPREGULATION;

BENZOQUINONES; BLOTTING, NORTHERN; CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LACTAMS, MACROCYCLIC; MALE; METALLOPROTEASES; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; QUINONES; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33745637200     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500852     Document Type: Article

References (41)

1. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732.
2. Powis G, Kirkpatrick L. Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther 2004; 3: 647-654.
3. Gradin K, McGuire J, Wenger RH, Kvietikova I, Whitelaw ML, Toftgard R et al. Functional interference between hypoxia and dioxin signal transduction pathways: Competition for recruitment of the Arnt transcription factor. Mol Cell Biol 1996; 16: 5221-5231.
4. Semenza GL. Hypoxia-inducible factor 1: Oxygen homeostasis and disease pathophysiology. Trends Mol Med 2001; 7: 345-350.
5. Mazzucchelli R, Montironi R, Santinelli A, Lucarini G, Pugnaloni A, Biagini G. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 2000; 45: 72-79.
6. Tennant MK, Thrasher JB, Twomey PA, Birnbaum RS, Plymate SR. Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metabol 1996; 81: 411-420.
7. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002; 62: 3387-3394.
8. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1 alpha (HIF-1 alpha) and HIF-2 alpha in hypoxic gene regulation. Mol Cellular Biol 2003; 23: 9361-9374.
9. Wang V, Davis DA, Haque M, Huang LE, Yarchoan R. Differential gene up-regulation by hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in HEK293T cells. Cancer Res 2005; 65: 3299-3306.
10. Levy AP, Levy NS, Goldberg MA. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel Lindau protein. J Biol Chem 1996; 271: 25492-23497.
11. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-4613.
12. Ravindranath N, Wion D, Brachet P, Djakiew D. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 2001; 22: 432-443.
13. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92: 735-745.
14. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: Identification of a molecular progression switch. Cancer Res 2001; 61: 2736-2743.
15. Hrouda D, Nicol DL, Gardiner RA. The role of angiogenesis in prostate development and the pathogenesis of prostate cancer. Urol Res 2003; 30: 347-355.
16. Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S et al. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 2002; 8: 2714-2724.
17. Koong AC, Denko NC, Hudson KM, Schindler C, Swiersz L, Koch C et al. Candidate genes for the hypoxic tumor phenotype. Cancer Res 2000; 60: 883-887.
18. Canning MT, Postovit LM, Clarke SH, Graham CH. Oxygen-mediated regulation of gelatinase and tissue inhibitor of metalloproteinases-1 expression by invasive cells. Exp Cell Res 2001; 267: 88-94.
19. Himelstein BP, Asada N, Carlton MR, Collins MH. Matrix metalloproteinase-9 (MMP-9) expression in childhood osseous osteosarcoma. Med Pediatr Oncol 1998; 31: 471-474.
20. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradatioe pathway. J Biol Chem 2002;277:29936-29944.
21. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002; 8: S55-S61.
22. Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW et al. Geldanamycin induces degradation of hypoxia-inducible factor 1 alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002; 62: 2478-2482.
23. Minet E, Mottet D, Michel G, Roland I, Raes M, Remacle J et al. Hypoxia-induced activation of HIF-1, role of HIF-1 alpha-Hsp90 interaction. FEBS Lett 1999; 460: 251-256.
24. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
25. Forbes K, Webb MA, Sehgal I. Growth factor regulation of secreted matrix metalloproteinase and plasminogen activators in prostate cancer cells, normal prostate fibroblasts and normal osteoblasts. Prostate Cancer Prostatic Dis 2003; 6: 148-153.
26. Saramaki OR, Savinainen KJ, Nupponen NN, Bratt O, Visakorpi T. Amplification of hypoxia-inducible factor 1 alpha gene in prostate cancer. Cancer Genet Cytogenet 2001; 128: 31-34.
27. Jiang BH, Jiang GQ, Zheng JZ, Lu ZM, Hunter T, Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor. Cell Growth Differentiation 2001; 12: 363-369.
28. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM et al. Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60: 1541-1545.
29. Mottet D, Dumont V, Deccache Y, Demazy C, Ninane N, Raes M et al. Regulation of hypoxia-inducible factor-1 alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3 beta pathway in HepG2 cells. J Biol Chem 2003; 278: 31277-31285.
30. Zhong H, Semenza GL, Simons JW, De Marzo AM. Up-regulation of hypoxia-inducible factor 1 alpha is an early event in prostate carcinogenesis. Cancer Detect Prevent 2004; 28: 88-93.
31. Van Lieshout T, Stanisz J, Espiritu V, Richardson M, Singh G. A hypoxic response induced in MatLyLu cells by cobalt chloride results in an enhanced angiogenic response by the chick chorioallantoic membrane. Int J Oncol 2003; 23: 745-750.
32. Blagosklonny MV. Hsp-90-associated oncoproteins: Multiple targets of geldanamycin and its analogs. Leukemia 2002; 16: 455-462.
33. Hayashibara T, Yamada Y, Miyanishi T, Mori H, Joh T, Maeda T et al. Vascular endothelial growth factor and cellular chemotaxis: A possible autocrine pathway in adult T-cell leukemia cell invasion. Clin Cancer Res 2001; 7: 2719-2726.
34. Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003; 63: 1138-1143.
35. Postovit LM, Adams MA, Lash GE, Heaton JP, Graham CH. Oxygen-mediated regulation of tumor cell invasiveness - involvement of a nitric oxide signaling pathway. J Biol Chem 2002; 277: 35730-35737.
36. Zagzag D, Nomura M, Friedlander DR, Blanco CY, Gagner JP, Nomura N et al. Geldanamycin inhibits migration of glioma cells in vitro: A potential role for hypoxia-inducible factor (HIF-1 alpha) in glioma cell invasion. J Cellular Physiol 2003; 196: 394-402.
37. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002; 8: 986-993.
38. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000; 106: 511-521.
39. Sato Y. Transcription factor ETS-1 as a molecular target for angiogenesis inhibition. Hum Cell 1998; 11: 207-214.
40. Wang H, Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Circ Res 1998; 83: 832-840.
41. Hayashibara T, Yamada Y, Onimaru Y, Tsutsumi C, Nakayama S, Mori N et al. Matrix metalloproteinase-9 and vascular endothelial growth factor: A possible link in adult T-cell leukaemia cell invasion. Br J Haematol 2002; 116: 94-102.